BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

652 related articles for article (PubMed ID: 28410988)

  • 1. Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.
    Arce Vargas F; Furness AJS; Solomon I; Joshi K; Mekkaoui L; Lesko MH; Miranda Rota E; Dahan R; Georgiou A; Sledzinska A; Ben Aissa A; Franz D; Werner Sunderland M; Wong YNS; Henry JY; O'Brien T; Nicol D; Challacombe B; Beers SA; ; ; ; Turajlic S; Gore M; Larkin J; Swanton C; Chester KA; Pule M; Ravetch JV; Marafioti T; Peggs KS; Quezada SA
    Immunity; 2017 Apr; 46(4):577-586. PubMed ID: 28410988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fc-Optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models.
    Campbell JR; McDonald BR; Mesko PB; Siemers NO; Singh PB; Selby M; Sproul TW; Korman AJ; Vlach LM; Houser J; Sambanthamoorthy S; Lu K; Hatcher SV; Lohre J; Jain R; Lan RY
    Cancer Res; 2021 Jun; 81(11):2983-2994. PubMed ID: 33757978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic depletion of CCR8
    Van Damme H; Dombrecht B; Kiss M; Roose H; Allen E; Van Overmeire E; Kancheva D; Martens L; Murgaski A; Bardet PMR; Blancke G; Jans M; Bolli E; Martins MS; Elkrim Y; Dooley J; Boon L; Schwarze JK; Tacke F; Movahedi K; Vandamme N; Neyns B; Ocak S; Scheyltjens I; Vereecke L; Nana FA; Merchiers P; Laoui D; Van Ginderachter JA
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FcγR-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy.
    Chen X; Song X; Li K; Zhang T
    Front Immunol; 2019; 10():292. PubMed ID: 30863404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody.
    Weaver JD; Stack EC; Buggé JA; Hu C; McGrath L; Mueller A; Wong M; Klebanov B; Rahman T; Kaufman R; Fregeau C; Spaulding V; Priess M; Legendre K; Jaffe S; Upadhyay D; Singh A; Xu CA; Krukenberg K; Zhang Y; Ezzyat Y; Saddier Axe D; Kuhne MR; Meehl MA; Shaffer DR; Weist BM; Wiederschain D; Depis F; Gostissa M
    Oncoimmunology; 2022; 11(1):2141007. PubMed ID: 36352891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-CD25 monoclonal antibody Fc variants differentially impact regulatory T cells and immune homeostasis.
    Huss DJ; Pellerin AF; Collette BP; Kannan AK; Peng L; Datta A; Wipke BT; Fontenot JD
    Immunology; 2016 Jul; 148(3):276-86. PubMed ID: 27012310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remodeling of the tumor microenvironment via disrupting Blimp1
    Dixon ML; Luo L; Ghosh S; Grimes JM; Leavenworth JD; Leavenworth JW
    Mol Cancer; 2021 Nov; 20(1):150. PubMed ID: 34798898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity.
    Zammarchi F; Havenith K; Bertelli F; Vijayakrishnan B; Chivers S; van Berkel PH
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32912922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RA8, a human anti-CD25 antibody against human Treg cells.
    Arias RS; Flanagan ML; Miller KD; Nien YC; Hu P; Gray D; Khawli LA; Epstein AL
    Hybridoma (Larchmt); 2007 Jun; 26(3):119-30. PubMed ID: 17600493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effect of Antibody Fragments on CD25 Targeted Regulatory T Cell Near-Infrared Photoimmunotherapy.
    Okada R; Maruoka Y; Furusawa A; Inagaki F; Nagaya T; Fujimura D; Choyke PL; Kobayashi H
    Bioconjug Chem; 2019 Oct; 30(10):2624-2633. PubMed ID: 31498995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-7 Mediated Homeostatic Expansion of Human CD4+CD25+FOXP3+ Regulatory T Cells After Depletion With Anti-CD25 Monoclonal Antibody.
    Vignali D; Gürth CM; Pellegrini S; Sordi V; Sizzano F; Piemonti L; Monti P
    Transplantation; 2016 Sep; 100(9):1853-61. PubMed ID: 27306531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Depletion of regulatory T cells in tumors with an anti-CD25 immunotoxin induces CD8 T cell-mediated systemic antitumor immunity.
    Onda M; Kobayashi K; Pastan I
    Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4575-4582. PubMed ID: 30760587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined Cancer Immunotherapy Against Aurora Kinase A.
    Kaštánková I; Poláková I; Dušková M; Šmahel M
    J Immunother; 2016 May; 39(4):160-70. PubMed ID: 27070447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo depletion of CD4+FOXP3+ Treg cells by the PC61 anti-CD25 monoclonal antibody is mediated by FcgammaRIII+ phagocytes.
    Setiady YY; Coccia JA; Park PU
    Eur J Immunol; 2010 Mar; 40(3):780-6. PubMed ID: 20039297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function.
    Buchan SL; Dou L; Remer M; Booth SG; Dunn SN; Lai C; Semmrich M; Teige I; Mårtensson L; Penfold CA; Chan HTC; Willoughby JE; Mockridge CI; Dahal LN; Cleary KLS; James S; Rogel A; Kannisto P; Jernetz M; Williams EL; Healy E; Verbeek JS; Johnson PWM; Frendéus B; Cragg MS; Glennie MJ; Gray JC; Al-Shamkhani A; Beers SA
    Immunity; 2018 Nov; 49(5):958-970.e7. PubMed ID: 30446386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Administration of anti-CD25 mAb leads to impaired α-galactosylceramide-mediated induction of IFN-γ production in a murine model.
    Rosalia RA; Štěpánek I; Polláková V; Šímová J; Bieblová J; Indrová M; Moravcová S; Přibylová H; Bontkes HJ; Bubeník J; Sparwasser T; Reiniš M
    Immunobiology; 2013 Jun; 218(6):851-9. PubMed ID: 23182710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer.
    Saha A; Chatterjee SK
    Scand J Immunol; 2010 Feb; 71(2):70-82. PubMed ID: 20384858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments.
    Moreno-Vicente J; Willoughby JE; Taylor MC; Booth SG; English VL; Williams EL; Penfold CA; Mockridge CI; Inzhelevskaya T; Kim J; Chan HTC; Cragg MS; Gray JC; Beers SA
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo depletion of CD4+CD25+ regulatory T cells in cats.
    Smithberg SR; Fogle JE; Mexas AM; Reckling SK; Lankford SM; Tompkins MB; Dean GA
    J Immunol Methods; 2008 Jan; 329(1-2):81-91. PubMed ID: 17980384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells.
    Ko K; Yamazaki S; Nakamura K; Nishioka T; Hirota K; Yamaguchi T; Shimizu J; Nomura T; Chiba T; Sakaguchi S
    J Exp Med; 2005 Oct; 202(7):885-91. PubMed ID: 16186187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.